新闻源 财富源

2019年09月18日 星期三

中关村(000931)公告正文

中 关 村:独立董事意见

公告日期:2017-08-19

    独立董事意见                                                                                            共   4 页


                                                独立董事意见

         北京中关村科技发展(控股)股份有限公司(以下简称:公司)
  第六届董事会第五次会议于 2017 年 8 月 18 日召开,我们作为独立董
  事就相关议题发表独立意见如下:

        一、对 2016 年半年度利润分配预案的独立意见
         未经审计,公司2017年半年度实现归属于母公司所有者的净利润
  为-65,026,075.09元。鉴于当期亏损,公司2017年半年度不进行利润
  分配,也不利用公积金转增股本。
         我们同意公司2017年半年度不进行利润分配,也不利用公积金转
  增股本。

        二、关于控股股东及其他关联方占用公司资金情况的意见
         根据中国证券监督管理委员会、国务院国有资产监督管理委员会
  《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题
  的通知》(证监发[2003]56 号文)的有关要求,经认真审核,现就公司
  报告期关联方资金占用情况发表专项说明和独立意见如下:截止 2017
  年 6 月 30 日,公司不存在控股股东及其他关联方非经营性占用公司资
  金的情形。

        三、关于公司累计和当期对外担保情况的专项说明和独立意见
        根据中国证监会、中国银监会证监发[2005]120 号文《规范上市公
  司对外担保行为的通知》(以下简称:《通知》),我们对公司对外担保
  情况进行了认真核查。
       每笔担保的主要情况:
                                                                                                            单位:万元
                          公司及其子公司对外担保情况(不包括对子公司的担保)

                     担保额度                                                                                    是否为
                                  担保额 实际发生日期         实际担保金                               是否履
   担保对象名称      相关公告                                                   担保类型     担保期              关联方
                                   度      (协议签署日)         额                                   行完毕
                     披露日期                                                                                     担保

                     2001 年 05            2001 年 08 月 23                    连带责任保 2002 年 08
福州华电房地产公司                 1,500                               1,500                           否        否
                     月 18 日              日                                  证           月 23 日

中关村科技贸易中心 2002 年 10              2011 年 01 月 01                    连带责任保
                                   112.9                               112.9                阶段       否        否
商品房、蓝筹名座、 月 10 日                日                                  证


                                                              第 1 页
     独立董事意见                                                                                         共   4 页

蓝筹名居承购人

蓝筹名座商品房承购 2002 年 02            2011 年 01 月 01                    连带责任保
                                 32.00                               32.00                阶段       否        否
人                   月 02 日            日                                  证

哈尔滨中关国际项目                       2011 年 01 月 01                    连带责任保
                                236.89                           236.89                   阶段       否        否
商品房承购人                             日                                  证

哈尔滨中关国际项目                       2011 年 01 月 01                    连带责任保
                                 24.88                               24.88                阶段       否        否
商品房承购人                             日                                  证

哈尔滨中关国际项目                       2011 年 01 月 01                    连带责任保
                                329.74                           329.74                   阶段       否        否
商品房承购人                             日                                  证

哈尔滨中关国际项目                       2011 年 01 月 01                    连带责任保
                                106.96                           106.96                   阶段       否        否
商品房承购人                             日                                  证

哈尔滨中关国际项目                       2013 年 09 月 18                    连带责任保
                                  9.32                                9.32                阶段       否        否
商品房承购人                             日                                  证

报告期内审批的对外担保额度合                                报告期内对外担保实际发
                                                       0                                                               0
计(A1)                                                    生额合计(A2)

报告期末已审批的对外担保额度                                报告期末实际对外担保余
                                                2,352.69                                                       2,352.69
合计(A3)                                                  额合计(A4)

                                         公司与子公司之间担保情况

                     担保额度                                                                                  是否为
                                担保额 实际发生日期         实际担保金                               是否履
     担保对象名称    相关公告                                                 担保类型     担保期              关联方
                                 度      (协议签署日)         额                                   行完毕
                     披露日期                                                                                   担保

北京华素制药股份有 2015 年 08            2015 年 09 月 14                    连带责任保 2019 年 9
                                13,000                               9,300                           否        否
限公司               月 13 日            日                                  证;抵押      月 14 日

北京华素制药股份有 2015 年 10            2015 年 10 月 21                    连带责任保 2019 年 10
                                 5,000                               5,000                           否        否
限公司               月 17 日            日                                  证           月 21 日

北京中实混凝土有限 2015 年 10            2015 年 10 月 26                    连带责任保 2019 年 10
                                 2,000                               2,000                           否        否
责任公司             月 17 日            日                                  证           月 26 日

北京中实上庄混凝土 2016 年 09            2016 年 11 月 03                    连带责任保 2019 年 11
                                15,000                           15,000                              否        否
有限责任公司         月 07 日            日                                  证           月 03 日

北京华素制药股份有 2017 年 1             2017 年 06 月 08                    连带责任保 2020 年 05
                                 6,000                               4,000                           否        否
限公司               月 17 日            日                                  证           月 30 日

北京华素制药股份有 2016 年 04            2016 年 04 月 26                    连带责任保 2021 年 04
                                 5,000                               5,000                           否        否
限公司               月 26 日            日                                  证           月 26 日

北京中关村科技发展 2016 年 04            2016 年 04 月 19                    连带责任保 2020 年 04
                                 8,000                               7,000                           否        否
(控股)股份有限公司 月 26 日              日                                  证           月 19 日

山东中关村医药科技 2017 年 05            2017 年 05 月 12                    连带责任保 2024 年 05
                                 8,000                          4,483.63                             否        否
发展有限公司         月 10 日                         日                     证           月 12 日

北京华素制药股份有 2017 年 06
                                 5,000                 0                0
限公司               月 16 日


                                                            第 2 页
    独立董事意见                                                                                          共   4 页


北京华素制药股份有 2017 年 01
                                 3,000                 0                0
限公司             月 17 日

报告期内审批对子公司担保额度                                报告期内对子公司担保实
                                                  22,000                                                        8,483.63
合计(B1)                                                  际发生额合计(B2)

报告期末已审批的对子公司担保                                报告期末对子公司实际担
                                                  70,000                                                       51,783.63
额度合计(B3)                                              保余额合计(B4)

                                         子公司对子公司的担保情况

                    担保额度                                                                                    是否为
                                担保额 实际发生日期         实际担保金                               是否履
   担保对象名称     相关公告                                                  担保类型    担保期                关联方
                                 度      (协议签署日)         额                                   行完毕
                    披露日期                                                                                     担保

北京华素制药股份有 2016 年 09            2016 年 10 月 27                    连带责任保 2020 年 10
                                18,000                           16,000                              否         否
限公司             月 07 日              日                                  证;抵押     月 27 日

北京华素制药股份有 2017 年 01            2017 年 01 月 20                    连带责任保 2020 年 01
                                 7,000                               7,000                           否         否
限公司             月 17 日              日                                  证          月 20 日

报告期内审批对子公司担保额度                                报告期内对子公司担保实
                                                    7000                                                             7000
合计(C1)                                                  际发生额合计(C2)

报告期末已审批的对子公司担保                                报告期末对子公司实际担
                                                  25,000                                                         23,000
额度合计(C3)                                              保余额合计(C4)

                                   公司担保总额(即前三大项的合计)

报告期内审批担保额度合计                                    报告期内担保实际发生额
                                                  29,000                                                       15,483.63
(A1+B1+C1)                                                合计(A2+B2+C2)

报告期末已审批的担保额度合计                                报告期末实际担保余额合
                                               97,352.69                                                       77,136.32
(A3+B3+C3)                                                计(A4+B4+C4)

实际担保总额(即 A4+B4+C4)占公司净资产的比例                                                                    50.87%

其中:

为股东、实际控制人及其关联方提供担保的余额(D)                                                                         0

直接或间接为资产负债率超过 70%的被担保对象提供的债
                                                                                                               19,483.63
务担保余额(E)

担保总额超过净资产 50%部分的金额(F)                                                                           13,13.42

上述三项担保金额合计(D+E+F)                                                                                  20,797.05

对未到期担保,报告期内已发生担保责任或可能承担连带
                                                                                                                       无
清偿责任的情况说明(如有)

违反规定程序对外提供担保的说明(如有)                                                                                 无

         截止 2017 年 06 月 30 日,公司对外担保余额(不包括对子公司的
  担保)为 2,352.69 万元,占公司最近一期经审计的归属于母公司净资
  产的 1.55%;对外担保余额(含为合并报表范围内的公司提供的担保)


                                                            第 3 页
独立董事意见                                             共   4 页


77,136.32 万元,占公司最近一期经审计的归属于母公司净资产的
50.87%。
    截止 2017 年 06 月 30 日,担保余额与 2016 年 12 月 31 日相比减
少 6,412.48 万元,主要包括:公司及其子公司对外担保增加 63.89 万
元;公司与子公司之间的担保减少 13,476.37 万元;子公司对子公司
的担保增加 7,000 万元。
    公司对外担保事项全部按照法律法规、公司章程和其他制度规定
履行了必要的审议程序。
    2011 年 3 月 31 日,经公司第四届董事会 2011 年度第三次临时会
议审议通过《对外担保管理办法》,建立了完善的对外担保风险控制制
度。
    在定期报告和临时公告中,公司充分披露了对外担保的担保金额、
担保类型等详细情况和存在的风险。
    鉴于公司对外担保总额超过《通知》规定的最近一期经审计净资
产的 50%,故此今后上市公司任何一笔担保均需提交股东大会审批。

   四、关于公司《2017 年半年度募集资金存放与使用情况的专项报
告》的独立意见
    经核查,公司募集资金的存放和使用严格按照《上市公司监管指
引第 2 号—上市公司募集资金管理和使用的监管要求》、《深圳证券交
易所主板上市公司规范运作指引》等有关规定和公司《募集资金使用
管理办法》执行,并按照有关规定和要求及时、真实、准确、完整地
披露了募集资金使用的相关信息,不存在募集资金管理及信息披露违
规情况。我们认为:募集资金使用与存放符合有关法律法规、规范性
文件和公司制度的规定。


       独立董事:雷世文、屠鹏飞、黄峰



                                           二 O 一七年八月十八日

                                 第 4 页